Preclinical and clinical evidence have delivered the rationale for PD-1/PD-L1blockade as a millstone in cancer immunotherapy, rendering that induction of the PD-1/PD-L1 axis is respected as an efficient tool for tumor escape host tumor antigen-specific T-cell immunity. Here, PDCD1 is linked to neoplasm.